A Phase 4 interventional study of Apremilast (CC-10004) and Apremilast (CC-10004) Placebo in Arthritis, Psoriatic, sponsored by Amgen. Completed at 114 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Amgen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.
Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 5th largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 4, and was the 10th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
Tanta University · Sites in Egypt
Ages 18–70
Amgen
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 310 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 219 across the 17 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
21 studies in Arthritis, Psoriatic by Amgen: 1 open now, 1 under way, none of them phase 3. Of 20 finished, 13 (65%) have results posted.
Among the 21 studies in Arthritis, Psoriatic by Amgen, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 in phase 4, and was the 19th registered.
Amgen’s Arthritis, Psoriatic studies by the year they started, since 2000.
2 of the studies testing apremilast in Arthritis, Psoriatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07398651Tanta UniversityApremilast and Adalimumab in Psoriatic Arthritis Patients | 2026-12-30 |
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing apremilast in Arthritis, Psoriatic, from their registry updates:
Among Amgen’s 21 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. This study will compare the effects of apremilast to placebo on psoriatic arthritis subjects in which the number of affected joints is limited (greater than 1 but less or equal to 4). About 285 patients worldwide will take part in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will take ORAL tables of apremilast for up to 48 weeks (30 mg twice daily). Subjects may also receive stable doses of background therapy (standard or care) with NSAIDs, glucorticosteroids and 1 csDMARD as permitted by protocol. After wk. 24, subjects may change the dose /type of permitted Psoriatic Arthritis medications
Drug: Apremilast (CC-10004)
Subjects will take placebo for up to 24 weeks (twice daily). Subjects may also receive stable doses of background therapy ( standard of care) with NSAIDs, glucocorticosteroids and 1 csDMARD as permitted by protocol. After wk 24, subjects may change the dose /type of permitted PsA medications.
Other: Apremilast (CC-10004) Placebo
Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive "dummy" titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles.
Also known as: Otezla
Subjects randomized to placebo will receive "dummy" dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles
Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16
MDA is defined as tender joint counts (TJC) ≤ 1 and SJC ≤ 1 plus 3 of the following 5 criteria: 1. psoriasis body surface area (BSA) ≤ 3% 2. patient's pain visual analogue scale (VAS) on a 100 mm scale ≤ 15; where 0 indicates 'no pain' and 100 indicates 'pain as severe as can be imagined' 3. patient's global assessment of disease activity on a 100 mm scale ≤ 20, where 0 represents the lowest level of disease activity and 100 represents the highest. 4. physical function assessed by Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ 0.5; where 0 represents normal or no difficulty and 3 represents an inability to perform 5. enthesitis count ≤ 1 based on the Leeds Enthesitis Index; where 0 means nontender and 6 indicates 6 tender tendon insertions.
Time frame: Week 16
Percentage of Participants Who Achieved Remission or Low Disease Activity at Week 16 Based on Clinical Activity in Psoriatic Arthritis (cDAPSA)
The cDAPSA score is based on the numerical summation of 4 disease activity variables: tender and swollen joints, patient's global assessments of disease activity and assessment of pain (VAS). The cDAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. cDAPSA remission is defined as a DAPSA score ≤ 4 and low disease activity is defined as a cDAPSA score \> 4 but ≤ 13).
Time frame: Week 16
Percentage of Participants With SJC ≤ 1 at Week 16
The SJC was based on 66 joints and at week 16 is based on the sentinel joints (i.e., the joints that were affected at baseline). A SJC response is defined as a count ≤ 1.
Time frame: Week 16
Percentage of Participants With TJC ≤ 1 at Week 16
The TJC was based on 68 joints and at week 16 was based on the sentinel joints (i.e., the joints that were affected at baseline). A TJC response is defined as a count ≤ 1.
Time frame: Week 16
Percentage of Participants With Patient's Global Assessments of Disease Activity Score of ≤ 20 mm in the VAS at Week 16
The Patient's Global Assessments of Disease Activity is an assessment of how active a participant's psoriatic arthritis was on average during the last week. It was assessed on a VAS ranging from 0 to 100 mm, with a higher score indicating more disease activity. A response is defined as a score ≤ 20 mm.
Time frame: Week 16
Percentage of Participants With an Assessment of Pain Score ≤ 15 mm in VAS at Week 16
The Patients Pain VAS is the participant's assessment of how much pain they had, on average, during the last week in their joints due to psoriatic arthritis. The VAS score ranges from 0 to 100 mm, with a higher score indicating more pain.
Time frame: Week 16
Change From Baseline in Psoriatic Arthritis Impact of Disease 12-item for Clinical Trials (PsAID-12) Questionnaire Score at Week 16
The PsAID-12 Questionnaire is a 12-item, self-administered questionnaire that reflects the impact of psoriatic arthritis from the perspective of the participant. The overall score ranges from 0 (best status) to 10 (worst status), with a cut-off ≤ 4 representing patient-acceptable symptom state. Analysis was based on a mixed-effects model for repeated measures (MMRM), which included treatment group, time, treatment group by time interaction, prior/concomitant use of csDMARD (naive, prior use only, both prior and concomitant use) and baseline glucocorticosteroid use (yes/no) per IWRS data as factors, and baseline value as a covariate.
Time frame: Baseline and Week 16
Percentage of Participants With a Good or Moderate Psoriatic Arthritis Disease Activity (PASDAS) Score at Week 16
The PASDAS is a weighted index comprising assessments of joints, function, acute-phase response, quality of life, and patient and physician VAS. The score range of the PASDAS is 0 - 10, with worse disease activity represented by higher scores. A good response is defined as a PASDAS score of ≤ 3.2 with improvement from baseline ≥ 1.6 points. A moderate response is defined as a PASDAS score \> 3.2 with improvement from baseline ≥ 1.6 points; or PASDAS score \< 5.4 with improvement from baseline ≥ 0.8 but \< 1.6 points.
Time frame: Baseline and Week 16
Participants were enrolled at 80 study centers in Austria, Belgium, Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States from 31 December 2018 to the last participant's last study visit on 05 July 2023.
| Milestone | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Apremilast-extension Phase: Placebo Then Apremilast 30 mg | Apremilast-extension Phase: Continued Apremilast 30 mg |
|---|---|---|---|---|
| Started | 105 | 203 | 0 | 0 |
| Full analysis set | 105 | 203 | 0 | 0 |
| Safety analysis set | 104 | 204 | 0 | 0 |
| Escaped early at week 16 | 24 | 21 | 0 | 0 |
| Completed week 16 and continued | 92 | 172 | 0 | 0 |
| Completed | 87 | 162 | 0 | 0 |
| Not completed | 18 | 41 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 8 | 19 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 7 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 7 | 0 | 0 |
| Withdrew: Miscellaneous | 0 | 2 | 0 | 0 |
| Milestone | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Apremilast-extension Phase: Placebo Then Apremilast 30 mg | Apremilast-extension Phase: Continued Apremilast 30 mg |
|---|---|---|---|---|
| Started | 0 | 0 | 87 | 162 |
| Received 1 dose of investigational product | 0 | 0 | 86 | 160 |
| Completed | 0 | 0 | 77 | 133 |
| Not completed | 0 | 0 | 10 | 29 |
| Withdrew: Adverse event | 0 | 0 | 2 | 6 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 7 |
| Withdrew: Other | 0 | 0 | 0 | 7 |
MDA is defined as tender joint counts (TJC) ≤ 1 and SJC ≤ 1 plus 3 of the following 5 criteria: 1. psoriasis body surface area (BSA) ≤ 3% 2. patient's pain visual analogue scale (VAS) on a 100 mm scale ≤ 15; where 0 indicates 'no pain' and 100 indicates 'pain as severe as can be imagined' 3. patient's global assessment of disease activity on a 100 mm scale ≤ 20, where 0 represents the lowest level of disease activity and 100 represents the highest. 4. physical function assessed by Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ 0.5; where 0 represents normal or no difficulty and 3 represents an inability to perform 5. enthesitis count ≤ 1 based on the Leeds Enthesitis Index; where 0 means nontender and 6 indicates 6 tender tendon insertions.
| percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16 | 16.0 | 33.9 |
The cDAPSA score is based on the numerical summation of 4 disease activity variables: tender and swollen joints, patient's global assessments of disease activity and assessment of pain (VAS). The cDAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. cDAPSA remission is defined as a DAPSA score ≤ 4 and low disease activity is defined as a cDAPSA score \> 4 but ≤ 13).
| percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants Who Achieved Remission or Low Disease Activity at Week 16 Based on Clinical Activity in Psoriatic Arthritis (cDAPSA) | 51.8 | 70.2 |
The SJC was based on 66 joints and at week 16 is based on the sentinel joints (i.e., the joints that were affected at baseline). A SJC response is defined as a count ≤ 1.
| percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With SJC ≤ 1 at Week 16 | 69.0 | 74.0 |
The TJC was based on 68 joints and at week 16 was based on the sentinel joints (i.e., the joints that were affected at baseline). A TJC response is defined as a count ≤ 1.
| percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With TJC ≤ 1 at Week 16 | 44.4 | 66.2 |
The Patient's Global Assessments of Disease Activity is an assessment of how active a participant's psoriatic arthritis was on average during the last week. It was assessed on a VAS ranging from 0 to 100 mm, with a higher score indicating more disease activity. A response is defined as a score ≤ 20 mm.
| percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With Patient's Global Assessments of Disease Activity Score of ≤ 20 mm in the VAS at Week 16 | 19.1 | 30.4 |
The Patients Pain VAS is the participant's assessment of how much pain they had, on average, during the last week in their joints due to psoriatic arthritis. The VAS score ranges from 0 to 100 mm, with a higher score indicating more pain.
| percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With an Assessment of Pain Score ≤ 15 mm in VAS at Week 16 | 13.1 | 29.4 |
The PsAID-12 Questionnaire is a 12-item, self-administered questionnaire that reflects the impact of psoriatic arthritis from the perspective of the participant. The overall score ranges from 0 (best status) to 10 (worst status), with a cut-off ≤ 4 representing patient-acceptable symptom state. Analysis was based on a mixed-effects model for repeated measures (MMRM), which included treatment group, time, treatment group by time interaction, prior/concomitant use of csDMARD (naive, prior use only, both prior and concomitant use) and baseline glucocorticosteroid use (yes/no) per IWRS data as factors, and baseline value as a covariate.
| score on a scale | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Change From Baseline in Psoriatic Arthritis Impact of Disease 12-item for Clinical Trials (PsAID-12) Questionnaire Score at Week 16 | -0.42 ± 0.216 | -1.45 ± 0.178 |
The PASDAS is a weighted index comprising assessments of joints, function, acute-phase response, quality of life, and patient and physician VAS. The score range of the PASDAS is 0 - 10, with worse disease activity represented by higher scores. A good response is defined as a PASDAS score of ≤ 3.2 with improvement from baseline ≥ 1.6 points. A moderate response is defined as a PASDAS score \> 3.2 with improvement from baseline ≥ 1.6 points; or PASDAS score \< 5.4 with improvement from baseline ≥ 0.8 but \< 1.6 points.
| percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With a Good or Moderate Psoriatic Arthritis Disease Activity (PASDAS) Score at Week 16 | 42.7 | 59.9 |
Collected over Week 0 up to week 48 (end of extension phase), and a 4-week observational follow-up (up to 52 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-controlled Phase: Placebo | 0/104 (0%) | 6/104 (5.8%) | 18/104 (17.3%) |
| Placebo-controlled Phase: Apremilast 30 mg | 2/204 (1%) | 9/204 (4.4%) | 72/204 (35.3%) |
| Apremilast-exposure: Apremilast 30 mg During Placebo-controlled and Extension Phases | 2/291 (0.7%) | 15/291 (5.2%) | 103/291 (35.4%) |
| Event | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Apremilast-exposure: Apremilast 30 mg During Placebo-controlled and Extension Phases |
|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/104 | 2/204 | 2/291 |
| Atrial fibrillationCardiac disorders | 1/104 | 0/204 | 1/291 |
| CellulitisInfections and infestations | 1/104 | 0/204 | 1/291 |
| UrosepsisInfections and infestations | 1/104 | 0/204 | 0/291 |
| Troponin increasedInvestigations | 1/104 | 0/204 | 0/291 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/104 | 0/204 | 0/291 |
| Transient ischaemic attackNervous system disorders | 1/104 | 0/204 | 0/291 |
| DepressionPsychiatric disorders | 1/104 | 0/204 | 0/291 |
| Acute kidney injuryRenal and urinary disorders | 1/104 | 0/204 | 0/291 |
| Hypertensive crisisVascular disorders | 1/104 | 0/204 | 0/291 |
| Event | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Apremilast-exposure: Apremilast 30 mg During Placebo-controlled and Extension Phases |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 11/104 | 47/204 | 69/291 |
| NauseaGastrointestinal disorders | 4/104 | 22/204 | 28/291 |
| HeadacheNervous system disorders | 3/104 | 16/204 | 21/291 |
| COVID-19Infections and infestations | 3/104 | 7/204 | 19/291 |
| Age, Continuous(years) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| Mean | 50.2 ± 13.03 | 51.3 ± 12.25 | 50.9 ± 12.51 |
| Sex: Female, Male(Participants) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| Female | 51 | 118 | 169 |
| Male | 54 | 85 | 139 |
| Race/Ethnicity, Customized(Participants) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 3 |
| Asian | 1 | 4 | 5 |
| Black or African American | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| White | 99 | 192 | 291 |
| Not Collected or Unknown | 2 | 3 | 5 |
| Race/Ethnicity, Customized(Participants) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 16 | 29 |
| Not Hispanic or Latino | 91 | 185 | 276 |
| Not Reported | 1 | 2 | 3 |
Showing the first 100 of 114 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Dec 2018 to primary completion in Dec 2022, 47 months.
Results were first posted in Jan 2024, 1 year after primary completion.
Of 33 phase 4 interventional studies under Arthritis, Psoriatic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 37. This study's 47 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast